Press releases

Analysis of the data presented at the American College of Cardiology Annual Scientific Sessions

Manufacturing process changes were not submitted for FDA approval; no indication that changes pose any risk to patient safety

First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries

Clinical data presentations to include 12-month results for third-generation TAXUS® Element™ drug-eluting stent

A webcast of the March 2 session will be available. Learn how to tune in live or watch the replay

Article reported a case summary of a patient who had been implanted subcutaneously with a Cognis cardiac resynchronization therapy defibrillator

New structure, leadership team and targeted portfolio changes will focus on sales excellence and cost effectiveness

"We delivered a quarter in line with expectations," said Ray Elliott, President and CEO

Settles three patent disputes with Johnson & Johnson (J&J) that date back to 2003

The patents relate to coatings (drug and polymer) for drug-eluting stents

Boston Scientific will webcast its February 11 conference call with financial results and business highlights for Q4 and FY 2009. Learn how to tune in.

Multi-center, prospective study plans to enroll 187 patients at 11 centers worldwide over the next 18 months

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A webcast of the January 12 session will be available. Learn how to tune in live or watch the replay

MAPS clinical trial studying the coiling of intracranial aneurysms reaches its goal of 630 patients, enrolled at 47 hospitals in 11 countries

Company to contribute data to industry-sponsored Dual Antiplatelet Therapy (DAPT) Study

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding...

Former Tyco executive "will bring an impressive range of global management experience to our Board," said Pete Nicholas, Chairman of the Board

Company to use the net proceeds for general corporate purposes, including prepaying its bank term loan due April 2011

Company expects the offering to close on December 14, 2009, subject to standard closing conditions

A webcast of the December 1 session will be available. Learn how to tune in live or watch the replay

Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets

Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention

Results from two clinical studies will be presented at the Global Congress for Minimally Invasive Gynecology (AAGL)

COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices